Letter NWHN

TRADEMARK of the name JANESWAY was discontinued with the first corporate effort. The
name is not important, only the license to manufacturer correctly and provide the latex to
women worldwide. In any language, in any packaging, with any name: Get this to women
everywhere.

NATIONAL WOMEN’S HEALTH NETWORK
514 10th St, NW, Ste 400, Washington, DC 20004
(202 )347-1140, FAX (202) 347-1168
The only national public-interest membership organization
devoted solely to women and health.
December 2, 1997

RE: JANESWAY Panty Condom

TRADEMARK of the name JANESWAY was discontinued with the first corporate effort. The
name is not important, only the license to manufacturer correctly and provide the latex to
women worldwide. In any language, in any packaging, with any name: Get this to women
everywhere.On behalf of the National Women’s Health Network, I am writing to express our support for the ongoing development of the JANESWAY contraceptive device. As you know, the Network has historically advocated for the development of women-controlled contraceptive methods which protect against sexually- transmitted diseases, including HIV.

The JANESWAY condom has, in the earliest phases of research and testing, shown great potential as a highly acceptable contraceptive barrier device. We believe that this device could add to the handful of methods that are in the control of women. As the spectrum of barrier contraceptive choices is broadened, the numbers of women who are protected from STD’s including HIV will also increase.

Bringing new contraceptive technology such as JANESWAY from bench to medicine cabinets can only be accomplished with leadership and funding from contraceptive development organizations such as CONRAD and FHI, and federal research agencies such as the National Institutes of Health and United States Agency for International Development.

Women the world over need and deserve a broader range of contraceptive choices which are safe and effective…. The Network believes that the JANESWAY would provide women around the world with a more expansive field of contraceptive options.

NOTE THIS PARAGRAPH ABOVE: IT CAN ONLYBE DONE by government funding BUT THERE IS NO GOVERNMENT FUNDING AVAILABLE so it has NOT BEEN DONE.

There has never been a more urgent need to broaden the range of barrier methods. In America, the number of women diagnosed with the AIDS virus increased by 63% versus 12.8% for men, and heterosexual sex has become the leading mode of transmission to women, according to the Center for Disease Control. In 1996, the CDC reported that chlamydia and gonorrhea (two STD’s which make women more vulnerable to HIV) were the two most frequently reported infectious diseases in the United States and that women comprise the majority of these cases.

The Network believes that it is appropriate, indeed essential, that public research dollars support the continued clinical testing of the JANESWAY device. The federal government and contraceptive research organization have a vested responsibility in encouraging the development of “two for one” contraceptive methods and we urge support for JANESWAY and for women’s health.

We look forward to working with you to bring JANESWAY to women around the world.

Sincerely,

Cynthia A. Pearson
Executive Director

{Editor’s note #1: A “two for one” device is one that provides BOTH contraception and disease prevention (prophylaxis)}
NOTE PARAGRAPH THREE ABOVE: IT CAN ONLY BE DONE by government funding BUT THERE IS NO GOVERNMENT FUNDING AVAILABLE so it has NOT BEEN DONE.